Huntleigh Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.58M Buy
2,984
+107
+4% +$109K 0.5% 51
2026
Q1
$2.65M Buy
2,877
+161
+6% +$163K 0.45% 58
2025
Q4
$2.92M Sell
2,716
-26
-0.9% -$24.9K 0.49% 51
2025
Q3
$2.09M Sell
2,742
-94
-3% -$70K 0.36% 73
2025
Q2
$2.21M Sell
2,836
-9
-0.3% -$6.99K 0.43% 57
2025
Q1
$2.35M Buy
2,845
+1
+0% +$832 0.55% 50
2024
Q4
$2.2M Buy
+2,844
New +$2.35M 0.47% 52

Other funds holding LLY

Huntleigh Advisors's LLY Position: Q2 2026 in Review

Huntleigh Advisors increased its Eli Lilly (LLY) stake by 3.7% in Q2 2026, buying an estimated $109K and bringing the position to 2,984 shares worth $3.58M. The position accounts for 0.5% of the portfolio, ranked #51.

Huntleigh Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Huntleigh Advisors held 2,984 shares of Eli Lilly worth $3.58M as of Q2 2026.
  • Huntleigh Advisors bought 107 Eli Lilly shares in Q2 2026, an estimated $109K.
  • Eli Lilly made up 0.5% of Huntleigh Advisors's portfolio in Q2 2026, its #51 holding.
  • Huntleigh Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Huntleigh Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.